Compound theophlline ketotifen sustained released tablet and preparation method thereof

Abstract

The invention discloses a compound theophlline ketotifen sustained released tablet and a preparation method of the compound theophlline ketotifen sustained released tablet. The compound theophlline ketotifen sustained released tablet contains active ingredients and pharmaceutic adjuvants, wherein the active ingredients comprise theophylline and ketotifen fumarate, and the pharmaceutic adjuvants comprise ethyecellulose, carboxymethyl starch sodium, polyacrylic resin II, magnesium stearate and alcohol. The method provided by the invention is simple and feasible, the obtained product can permanently release the active ingredients, the plasma concentration is enabled to be stable, the variation range of the peak concentration and valley concentration is small, the taking dosage and times are reduced, and the side effects are small.

Description

technical field [0001] The invention relates to a slow-release medicine, in particular to a slow-release medicine composed of theophylline and ketotifen fumarate and a preparation method thereof. Background technique [0002] Asthma, chronic bronchitis, and airway obstructive pulmonary disease account for 10% of the total population. In the past thirty years, people have developed a large number of anti-asthma drugs and drugs for the treatment of chronic bronchitis. Salbutamol, Bricanyl, etc. have achieved great success in clinical short-term symptom relief, but it has been found that these drugs have poor effects on the delayed response of asthma and chronic asthma, and have rapid desensitization; glucocorticoids such as ground Cemethasone is ineffective in controlling the early symptoms of asthma, and after long-term use, it can cause endocrine disorders, high blood pressure, arteriosclerosis, gastrointestinal bleeding, electrolyte imbalance and other adverse reactions; T...

AI Technical Summary

Problems solved by technology

Salbutamol, Bricanyl, etc. have achieved great success in clinical short-term symptom relief, but it has been found that these drugs have poor effects on the delayed response of asthma and chronic asthma, and have rapid desensitization; glucocorticoids such as ground Cemethasone is ineffective in controlling the early symptoms of asthma, and after long-term use, it can cause endocrine disorders, high blood pressure, arteriosclerosis, gastrointestinal bleeding, electrolyte imbalance and other adverse reactions; Triene antagonists, cholinergic antagonists, etc., have a significant effect on the early response of asthma, but are not effective in the treatment of the delayed response of asthma and obstructive pulmonary disease.